Cargando…
Risk factors and outcomes associated with persistent vancomycin resistant Enterococcal Bacteremia
BACKGROUND: Prior studies have identified that vancomycin resistant enterococcus (VRE) bacteremia that persists for four days or more is an independent predictor of mortality. Despite this, there is no published data to identify those patients at highest risk of developing persistent VRE bacteremia....
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9670444/ https://www.ncbi.nlm.nih.gov/pubmed/36384497 http://dx.doi.org/10.1186/s12879-022-07864-8 |
_version_ | 1784832335650226176 |
---|---|
author | Fox, Emily Ha, David Bounthavong, Mark Meng, Lina Mui, Emily Holubar, Marisa Deresinski, Stanley Alegria, William |
author_facet | Fox, Emily Ha, David Bounthavong, Mark Meng, Lina Mui, Emily Holubar, Marisa Deresinski, Stanley Alegria, William |
author_sort | Fox, Emily |
collection | PubMed |
description | BACKGROUND: Prior studies have identified that vancomycin resistant enterococcus (VRE) bacteremia that persists for four days or more is an independent predictor of mortality. Despite this, there is no published data to identify those patients at highest risk of developing persistent VRE bacteremia. METHODS: This was a single center, retrospective, case-control study of adult patients with a VRE bloodstream infection (BSI). Case patients were those with persistent bacteremia (≥ 4 days despite VRE-directed therapy) and control patients were those with non-persistent bacteremia. Logistic regression was used to assess risk factors associated with persistent VRE BSIs. Secondary outcomes included in-hospital mortality, recurrent bacteremia, and breakthrough bacteremia. RESULTS: During the study period, 24/108 (22%) patients had persistently positive blood cultures. Risk factors for persistent bacteremia included severe neutropenia (OR 2.13), 4 out of 4 positive index blood cultures (OR 11.29) and lack of source control (OR 11.88). In an unadjusted analysis, no statistically significant differences in in-hospital mortality (58% versus 40%; p = 0.121), recurrent bacteremia (17% versus 6%; p = 0.090), or breakthrough bacteremia (13% versus 7%; p = 0.402) were observed between groups. CONCLUSION: Patients with severe neutropenia, 4 out of 4 positive index blood culture bottles, and lack of source control were more likely to develop persistent VRE bacteremia despite directed antibiotic treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07864-8. |
format | Online Article Text |
id | pubmed-9670444 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-96704442022-11-18 Risk factors and outcomes associated with persistent vancomycin resistant Enterococcal Bacteremia Fox, Emily Ha, David Bounthavong, Mark Meng, Lina Mui, Emily Holubar, Marisa Deresinski, Stanley Alegria, William BMC Infect Dis Research BACKGROUND: Prior studies have identified that vancomycin resistant enterococcus (VRE) bacteremia that persists for four days or more is an independent predictor of mortality. Despite this, there is no published data to identify those patients at highest risk of developing persistent VRE bacteremia. METHODS: This was a single center, retrospective, case-control study of adult patients with a VRE bloodstream infection (BSI). Case patients were those with persistent bacteremia (≥ 4 days despite VRE-directed therapy) and control patients were those with non-persistent bacteremia. Logistic regression was used to assess risk factors associated with persistent VRE BSIs. Secondary outcomes included in-hospital mortality, recurrent bacteremia, and breakthrough bacteremia. RESULTS: During the study period, 24/108 (22%) patients had persistently positive blood cultures. Risk factors for persistent bacteremia included severe neutropenia (OR 2.13), 4 out of 4 positive index blood cultures (OR 11.29) and lack of source control (OR 11.88). In an unadjusted analysis, no statistically significant differences in in-hospital mortality (58% versus 40%; p = 0.121), recurrent bacteremia (17% versus 6%; p = 0.090), or breakthrough bacteremia (13% versus 7%; p = 0.402) were observed between groups. CONCLUSION: Patients with severe neutropenia, 4 out of 4 positive index blood culture bottles, and lack of source control were more likely to develop persistent VRE bacteremia despite directed antibiotic treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07864-8. BioMed Central 2022-11-16 /pmc/articles/PMC9670444/ /pubmed/36384497 http://dx.doi.org/10.1186/s12879-022-07864-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Fox, Emily Ha, David Bounthavong, Mark Meng, Lina Mui, Emily Holubar, Marisa Deresinski, Stanley Alegria, William Risk factors and outcomes associated with persistent vancomycin resistant Enterococcal Bacteremia |
title | Risk factors and outcomes associated with persistent vancomycin resistant Enterococcal Bacteremia |
title_full | Risk factors and outcomes associated with persistent vancomycin resistant Enterococcal Bacteremia |
title_fullStr | Risk factors and outcomes associated with persistent vancomycin resistant Enterococcal Bacteremia |
title_full_unstemmed | Risk factors and outcomes associated with persistent vancomycin resistant Enterococcal Bacteremia |
title_short | Risk factors and outcomes associated with persistent vancomycin resistant Enterococcal Bacteremia |
title_sort | risk factors and outcomes associated with persistent vancomycin resistant enterococcal bacteremia |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9670444/ https://www.ncbi.nlm.nih.gov/pubmed/36384497 http://dx.doi.org/10.1186/s12879-022-07864-8 |
work_keys_str_mv | AT foxemily riskfactorsandoutcomesassociatedwithpersistentvancomycinresistantenterococcalbacteremia AT hadavid riskfactorsandoutcomesassociatedwithpersistentvancomycinresistantenterococcalbacteremia AT bounthavongmark riskfactorsandoutcomesassociatedwithpersistentvancomycinresistantenterococcalbacteremia AT menglina riskfactorsandoutcomesassociatedwithpersistentvancomycinresistantenterococcalbacteremia AT muiemily riskfactorsandoutcomesassociatedwithpersistentvancomycinresistantenterococcalbacteremia AT holubarmarisa riskfactorsandoutcomesassociatedwithpersistentvancomycinresistantenterococcalbacteremia AT deresinskistanley riskfactorsandoutcomesassociatedwithpersistentvancomycinresistantenterococcalbacteremia AT alegriawilliam riskfactorsandoutcomesassociatedwithpersistentvancomycinresistantenterococcalbacteremia |